Chronic itch has often been dismissed as a minor skin complaint; however, experts view it as a warning sign of deeper disease ...
Prurigo nodularis (PN) is extremely itchy skin that leads to a bumpy rash. The rash appears as the result of repeated scratching, picking, or rubbing of the itchy areas of the skin. There isn’t one ...
Please provide your email address to receive an email when new articles are posted on . By week 12, itch and pain scores decreased 78.3% and 53.7% in the prurigo nodular and chronic pruritus of ...
A drug approved to treat eczema provided significant improvement in the symptoms of patients with severe itching diseases that currently have no targeted treatments, according to a new study. The drug ...
Nemolizumab (Mitchga) is gearing up to be a potential new treatment for prurigo nodularis, with further phase 3 data supporting its efficacy and safety reported this month at the annual meeting of the ...
ZUG, Switzerland--(BUSINESS WIRE)--Galderma presented the latest data from its pivotal phase III OLYMPIA 2 trial at the 25 th World Congress of Dermatology (WCD) in Singapore. The results highlight ...
Please provide your email address to receive an email when new articles are posted on . The European Commission has approved Dupixent for the treatment of moderate to severe prurigo nodularis in ...
ZUG, Switzerland--(BUSINESS WIRE)--Galderma today announced that the New England Journal of Medicine has published full results from the phase III OLYMPIA 2 trial evaluating the efficacy and safety of ...
After 52 weeks of continuous treatment, 88.9% of patients had a ≥4-point improvement in pruritus score, and 81.5% had a ≥4-point improvement in sleep disturbance. Improvement in skin lesions occurred ...
Paris and Tarrytown, N.Y. Dec. 15, 2022 The European Commission (EC) has expanded the marketing authorization for Dupixent® (dupilumab) in the European Union to treat adults with moderate-to-severe ...
NEMLUVIO is the first authorized monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31.1 IL-31 is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results